UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of enzyme inhibition and medicinal chemistry, ISSN 1475-6366, 2002
Journal
European journal of medicinal chemistry, ISSN 0223-5234, 10/2014, Volume 85, pp. 418 - 437
Inhibitor | Cross-coupling reaction | DNPH1 | Nucleoside analogues | Crystal structure | Cancer | Purine Nucleotides - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Enzyme Inhibitors - chemical synthesis | Molecular Targeted Therapy | Purine Nucleotides - chemistry | N-Glycosyl Hydrolases - chemistry | Purine Nucleotides - metabolism | Antineoplastic Agents - metabolism | Enzyme Inhibitors - chemistry | Drug Design | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Chemistry Techniques, Synthetic | Enzyme Inhibitors - metabolism | N-Glycosyl Hydrolases - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Rats | Nuclear Proteins - metabolism | Purine Nucleotides - chemical synthesis | Antineoplastic Agents - chemistry | Nuclear Proteins - chemistry | N-Glycosyl Hydrolases - metabolism | Animals | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Conformation | Molecular Docking Simulation | Drug Screening Assays, Antitumor | Enzymes | Colon cancer | Leukemia | Crystals | Hydrolases | Nucleotides | Structure | Index Medicus | Nuclear Proteins/chemistry | Purine Nucleotides/metabolism | Proto-Oncogene Proteins/antagonists & inhibitors | Enzyme Inhibitors/metabolism | Enzyme Inhibitors/pharmacology | Life Sciences | Antineoplastic Agents/pharmacology | N-Glycosyl Hydrolases/antagonists & inhibitors | Nuclear Proteins/antagonists & inhibitors | N-Glycosyl Hydrolases/metabolism | Nuclear Proteins/metabolism | Purine Nucleotides/chemistry | Enzyme Inhibitors/chemistry | Purine Nucleotides/chemical synthesis | Enzyme Inhibitors/chemical synthesis | Antineoplastic Agents/metabolism | N-Glycosyl Hydrolases/chemistry | Proto-Oncogene Proteins/chemistry | Biochemistry, Molecular Biology | Proto-Oncogene Proteins/metabolism | Purine Nucleotides/pharmacology | Antineoplastic Agents/chemistry | Antineoplastic Agents/chemical synthesis
Journal Article
2009, ISBN 1402095635, ix, 125
Book
2001, Infectious disease and therapy, ISBN 9780824704612, Volume 25., xi, 310
Book
2010, Recent results in cancer research, ISBN 9783540782803, Volume 180., xiv, 231
Book
Expert opinion on investigational drugs, ISSN 1354-3784, 06/2017, Volume 26, Issue 6, pp. 699 - 711
PIM-Kinase inhibitor | proteasome inhibitor | CDK inhibitor | AKT inhibitor | Multiple myeloma | single-agent | alkylator | kinesin-spindle protein inhibitor | MEK inhibitor | monoclonal antibody | BCL-2 inhibitor | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Drugs, Investigational - pharmacology | Proteasome Inhibitors - pharmacology | Antibodies, Monoclonal - pharmacology | Humans | Proteasome Inhibitors - administration & dosage | Drugs, Investigational - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Proteasome Inhibitors - therapeutic use | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Animals | Antibodies, Monoclonal - administration & dosage | Drug Design | Drugs, Investigational - administration & dosage | Antineoplastic Agents - pharmacology | Index Medicus
Journal Article
1998, Lung biology in health and disease, ISBN 9780824701673, Volume 120., xviii, 493
Book
Genes & development, ISSN 0890-9369, 05/2013, Volume 27, Issue 10, pp. 1101 - 1114
Huwe1 | c-Myc | Mule | Ras | p21 | Miz1 | Genetics & Heredity | Life Sciences & Biomedicine | Developmental Biology | Science & Technology | Cell Biology | Protein Inhibitors of Activated STAT - deficiency | Tetradecanoylphorbol Acetate - pharmacology | 9,10-Dimethyl-1,2-benzanthracene - pharmacology | Male | Protein Inhibitors of Activated STAT - metabolism | Cyclin-Dependent Kinase Inhibitor p15 - biosynthesis | Oncogene Protein p21(ras) - metabolism | Cyclin-Dependent Kinase Inhibitor p16 | Oncogene Protein p21(ras) - antagonists & inhibitors | Cyclin-Dependent Kinase Inhibitor p21 - genetics | Cell Transformation, Neoplastic - genetics | Cyclin-Dependent Kinase Inhibitor p15 - genetics | Nuclear Proteins - deficiency | Protein Inhibitors of Activated STAT - genetics | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Female | Nuclear Proteins - genetics | Protein Inhibitors of Activated STAT - antagonists & inhibitors | Skin Neoplasms - pathology | Cyclin-Dependent Kinase Inhibitor p21 - biosynthesis | Signal Transduction | Down-Regulation | Cells, Cultured | Ubiquitin-Protein Ligases - metabolism | Nuclear Proteins - metabolism | Skin Neoplasms - chemically induced | Proto-Oncogene Proteins c-myc - metabolism | Mice, Knockout | Skin Neoplasms - metabolism | Keratinocytes - pathology | Animals | Tumor Suppressor Protein p53 | Keratinocytes - drug effects | Keratinocytes - metabolism | Nuclear Proteins - antagonists & inhibitors | Proto-Oncogene Proteins c-myc - deficiency | Skin Neoplasms - genetics | Proto-Oncogene Proteins c-myc - antagonists & inhibitors | Ubiquitin-Protein Ligases - deficiency | Mice | Proto-Oncogene Proteins c-myc - genetics | Cyclin-Dependent Kinase Inhibitor p15 - metabolism | Genes, ras | Ubiquitin-Protein Ligases - genetics | Oncogene Protein p21(ras) - genetics | Carcinogenesis | Ras genes | Analysis | Index Medicus | Research Paper
Journal Article
2006, ISBN 9780470012949, xvii, 350
Blood Vessels | Endothelial Cells | Effect of drugs on | drug therapy | Blood-vessels | Gene Therapy | methods | Neovascularization, Pathologic | drug effects | Angiogenesis Inhibitors | Neoplasms | Drug Delivery Systems | Chemotherapy | Neovascularization | therapeutic use | Neovascularization inhibitors | Cancer
Book
The Journal of immunology (1950), ISSN 0022-1767, 01/2004, Volume 172, Issue 1, pp. 567 - 576
Life Sciences & Biomedicine | Immunology | Science & Technology | Protein Binding - genetics | Protein Biosynthesis | Interleukin-6 - antagonists & inhibitors | Humans | Tumor Necrosis Factor-alpha - genetics | Immunoglobulins - genetics | Lipopolysaccharides - antagonists & inhibitors | RNA, Messenger - metabolism | Suppressor of Cytokine Signaling Proteins | Repressor Proteins - antagonists & inhibitors | Antigens, CD - metabolism | Trans-Activators - physiology | Protein Tyrosine Phosphatases - antagonists & inhibitors | RNA, Messenger - biosynthesis | Protein Tyrosine Phosphatases - genetics | Inflammation Mediators - physiology | Glycoproteins - genetics | DNA-Binding Proteins - physiology | Protein Tyrosine Phosphatases - biosynthesis | DNA-Binding Proteins - antagonists & inhibitors | Signal Transduction - genetics | DNA - metabolism | Down-Regulation - genetics | Macrophages - metabolism | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | Repressor Proteins - biosynthesis | Up-Regulation - immunology | Interleukin-10 - antagonists & inhibitors | Lipopolysaccharides - pharmacology | Adenoviruses, Human - genetics | Interleukin-10 - immunology | Tumor Necrosis Factor-alpha - biosynthesis | Phosphorylation | Tissue Inhibitor of Metalloproteinase-1 - biosynthesis | Antigens, CD - biosynthesis | Receptors, Cell Surface | Receptors, IgG - biosynthesis | Receptors, IgG - antagonists & inhibitors | Interleukin-10 - physiology | Signal Transduction - immunology | Tissue Inhibitor of Metalloproteinase-1 - metabolism | Signaling Lymphocytic Activation Molecule Family Member 1 | Receptors, Tumor Necrosis Factor - antagonists & inhibitors | RNA, Messenger - antagonists & inhibitors | Receptors, Tumor Necrosis Factor, Type II | Trans-Activators - genetics | Inflammation Mediators - antagonists & inhibitors | Trans-Activators - biosynthesis | Immunoglobulins - biosynthesis | Macrophages - immunology | Inflammation Mediators - immunology | Receptors, Tumor Necrosis Factor - metabolism | Immune Sera - pharmacology | Proteins - physiology | Cells, Cultured | Glycoproteins - antagonists & inhibitors | Histocompatibility Antigens Class II - biosynthesis | Tissue Inhibitor of Metalloproteinase-1 - antagonists & inhibitors | Transcription Factors - antagonists & inhibitors | Transcription Factors - biosynthesis | Up-Regulation - genetics | DNA-Binding Proteins - genetics | DNA - antagonists & inhibitors | Glycoproteins - biosynthesis | Suppressor of Cytokine Signaling 3 Protein | Down-Regulation - immunology | Interleukin-6 - biosynthesis | Receptors, Tumor Necrosis Factor - biosynthesis | STAT3 Transcription Factor | Trans-Activators - antagonists & inhibitors | Genetic Vectors | DNA-Binding Proteins - biosynthesis | Tumor Necrosis Factor-alpha - antagonists & inhibitors | SOCS-3 protein | Index Medicus | Abridged Index Medicus
Journal Article
Expert opinion on drug discovery, ISSN 1746-0441, 09/2013, Volume 8, Issue 9, pp. 1095 - 1116
acyl t-RNA synthase inhibitor | Clp protease inhibitor | methicillin-resistant Staphylococcus aureus | two-component system inhibitor | elongation factor G inhibitor | linezolid | antibacterial agents | combination therapy | daptomycin | vancomycin | β-lactamase inhibitor | antibacterial vaccine | dihydropteroate synthase inhibitor | peptidoglycan biosynthesis inhibitor | Pol IIIC inhibitor | electron transport inhibitor | RNA-polymerase inhibitor | phage therapy | peptide deformylase inhibitor | menaquinone biosynthesis inhibitor | Gram-positive pathogens | antibiotics | antimicrobial peptides | dihydrofolate reductase inhibitor | FAS II inhibitor | Linezolid | Peptide deformylase inhibitor | Daptomycin | Dihydropteroate synthase inhibitor | Vancomycin | Combination therapy | Antimicrobial peptides | Menaquinone biosynthesis inhibitor | Antibacterial vaccine | Dihydrofolate reductase inhibitor | Acyl t-RNA synthase inhibitor | Elongation factor G inhibitor | Antibacterial agents | Electron transport inhibitor | Peptidoglycan biosynthesis inhibitor | Antibiotics | Methicillin-resistant Staphylococcus aureus | Phage therapy | Two-component system inhibitor | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Anti-Bacterial Agents - therapeutic use | Animals | Bacterial Infections - drug therapy | Drug Resistance, Multiple, Bacterial | Humans | Drug Discovery | Methicillin-Resistant Staphylococcus aureus | Index Medicus | elongation factor G (EF-G) inhibitor | peptide deformylase (PDF) inhibitor | methicillin-resistant Staphylococcus aureus (MRSA) | PolIIC inhibitor | β5 -lactamase inhibitor
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 04/2018, Volume 61, Issue 8, pp. 3582 - 3594